Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

OCX

Oncocyte Corporation

Apr 15 • 04:00PM ET

2.53

Dollar change -0.18
Percentage change -6.64	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF DFSV DCOR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-23.85	Insider Own	8.01%	Shs Outstand	8.26M	Perf Week	-12.76%
Market Cap	20.90M	Forward P/E	-	EPS next Y	-0.89	Insider Trans	371.40%	Shs Float	7.60M	Perf Month	-14.24%
Income	-29.13M	PEG	-	EPS next Q	-0.57	Inst Own	54.92%	Short Float	2.36%	Perf Quarter	-24.70%
Sales	1.50M	P/S	13.93	EPS this Y	22.52%	Inst Trans	-33.80%	Short Ratio	3.61	Perf Half Y	-24.45%
Book/sh	2.48	P/B	1.02	EPS next Y	58.89%	ROA	-	Short Interest	0.18M	Perf Year	-61.31%
Cash/sh	1.14	P/C	2.22	EPS next 5Y	-	ROE	-	52W Range	2.08 - 6.90	Perf YTD	1.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	14.72%	ROI	-104.79%	52W High	-63.33%	Beta	0.78
Dividend TTM	-	Quick Ratio	2.11	Sales past 5Y	16.25%	Gross Margin	50.17%	52W Low	21.63%	ATR (14)	0.15
Dividend Ex-Date	-	Current Ratio	1.49	EPS Y/Y TTM	-82.13%	Oper. Margin	-1478.24%	RSI (14)	24.07	Volatility	9.18% 4.49%
Employees	-	Debt/Eq	0.11	Sales Y/Y TTM	-	Profit Margin	-1938.06%	Recom	1.00	Target Price	4.30
Option/Short	No / Yes	LT Debt/Eq	0.09	EPS Q/Q	-28.57%	Payout	-	Rel Volume	2.14	Prev Close	2.71
Sales Surprise	39.56%	EPS Surprise	61.99%	Sales Q/Q	-69.12%	Earnings	Apr 12 BMO	Avg Volume	49.56K	Price	2.53
SMA20	-14.51%	SMA50	-14.80%	SMA200	-23.20%	Trades		Volume	106,012	Change	-6.64%

Date	Action	Analyst	Rating Change	Price Target Change
May-24-22	Downgrade	Stephens	Overweight → Equal-Weight
Mar-14-22	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Jan-07-22	Initiated	Stephens	Overweight	$3.10
Jan-06-22	Resumed	Piper Sandler	Overweight	$3.10
Mar-17-21	Resumed	Needham	Buy	$8
Jan-07-21	Upgrade	The Benchmark Company	Speculative Buy → Buy	$6
Dec-16-20	Upgrade	Piper Sandler	Neutral → Overweight	$2 → $4
Nov-30-20	Initiated	BTIG Research	Buy	$5
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$5
Jul-30-20	Reiterated	The Benchmark Company	Speculative Buy	$7 → $6
Jul-01-20	Downgrade	Piper Sandler	Overweight → Neutral
Jun-30-20	Downgrade	Chardan Capital Markets	Buy → Neutral	$2
Jun-02-20	Initiated	Needham	Buy	$4
Feb-13-19	Initiated	Piper Jaffray	Overweight	$6
Jan-29-19	Upgrade	Janney	Neutral → Buy
Dec-19-18	Resumed	Lake Street	Buy

Show Previous Ratings

Apr-12-24 10:52AM	OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -8.60%
06:00AM	Oncocyte Reports Full Year 2023 Financial Results (GlobeNewswire)
Apr-11-24 09:46PM	Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
05:30PM	Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay (GlobeNewswire)
Apr-09-24 04:05PM	Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
08:00AM	Loading…
Jan-16-24 08:00AM	Oncocyte to Present at the Sequire Investor Summit in Puerto Rico (GlobeNewswire)
Dec-06-23 08:00AM	Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays (GlobeNewswire)
Nov-09-23 08:27AM	OncoCyte Corp (OCX) Reports Q3 2023 Financial Results with Key Product Launches on the Horizon (GuruFocus.com) +29.71%
07:00AM	Oncocyte Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-03-23 08:30AM	Oncocyte to Announce Third Quarter 2023 Financial Results (GlobeNewswire) +8.09%
Sep-18-23 08:00AM	Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier (ACCESSWIRE) +5.49%
Sep-06-23 08:00AM	Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (ACCESSWIRE)
Aug-28-23 08:30AM	Oncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage (ACCESSWIRE)
Aug-10-23 07:00AM	Oncocyte Reports Second Quarter 2023 Financial Results (ACCESSWIRE)
Aug-09-23 08:00AM	Oncocyte Regains Compliance With Nasdaq Listing Requirements (ACCESSWIRE)
08:30AM	Loading…
Aug-08-23 08:30AM	Oncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference (ACCESSWIRE) -5.29%
Aug-03-23 08:00AM	Oncocyte To Announce Second Quarter 2023 Financial Results (ACCESSWIRE)
Jul-25-23 09:08AM	VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients (GlobeNewswire)
Jul-24-23 01:35PM	Oncocyte Announces 1-For-20 Reverse Stock Split (GlobeNewswire) -9.57%
Jun-27-23 08:30AM	Oncocyte Begins Manufacturing Transplant Blood Test (GlobeNewswire)
Jun-01-23 04:15PM	Oncocyte Corporation to Present at the LD Micro Invitational XIII (Newsfile) +6.55%
May-11-23 08:00AM	Oncocyte Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-27-23 04:59PM	Oncocyte To Announce First Quarter 2023 Financial Results (GlobeNewswire) +9.86%
Apr-18-23 08:45AM	Oncocyte Presents New Data at AACR (GlobeNewswire)
Apr-12-23 04:15PM	Oncocyte Announces Reduction in Force (GlobeNewswire)
Apr-07-23 08:24AM	Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer (GlobeNewswire)
Apr-03-23 08:00AM	Oncocyte Pricing of $13.86 Million Public Offering of Common Stock (GlobeNewswire) -10.41%
Mar-31-23 05:00PM	Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K (GlobeNewswire) +26.57%
Mar-29-23 04:01PM	Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call (GlobeNewswire) +5.52%
Mar-15-23 04:01PM	Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -20.00%
09:00AM	Loading…
Mar-02-23 09:00AM	Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer (GlobeNewswire)
Feb-22-23 08:00AM	Oncocyte Completes Razor Genomics Transaction (GlobeNewswire)
Dec-16-22 08:19AM	Oncocyte cuts 40% of staff (MarketWatch) -21.95%
08:00AM	Oncocyte Announces Initiatives to Focus Corporate Strategy (GlobeNewswire)
Nov-30-22 06:05PM	Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors (GlobeNewswire)
06:00PM	Oncocyte Announces Executive Leadership Changes (GlobeNewswire)
Nov-10-22 04:30PM	Oncocyte Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-27-22 04:01PM	Oncocyte to Announce Third Quarter 2022 Financial Results (GlobeNewswire) -13.50%
Oct-06-22 08:00AM	DetermaIO Clinical Test to be used in SWOG Cancer Research Network Biomarker Study for Breast Cancer (GlobeNewswire)
Sep-07-22 08:00AM	Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on DetermaRx to CMS (GlobeNewswire)
Aug-31-22 04:01PM	Oncocyte to Participate at the Lake Street 6th Annual Best Ideas Growth Conference (GlobeNewswire)
Aug-30-22 04:27PM	Oncocyte Announces Five-Year VA Contract for DetermaRx (GlobeNewswire) -6.93%
Aug-24-22 08:00AM	Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer (GlobeNewswire)
Aug-10-22 04:05PM	Oncocyte Reports Second Quarter 2022 Financial Results (GlobeNewswire) +10.57%
Aug-03-22 04:01PM	Oncocyte to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-01-22 11:33AM	The past year for OncoCyte (NASDAQ:OCX) investors has not been profitable (Simply Wall St.)
05:00AM	Oncocyte Announces the Appointment of John Peter Gutfreund as Independent Member of Its Board of Directors Effective July 28, 2022 (GlobeNewswire)
Jul-27-22 04:01PM	Oncocyte to Announce Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-13-22 08:00AM	Oncocyte Announces Market Entry and Early Adopter Program for Transplant Rejection Monitoring Business (GlobeNewswire) +5.75%
Jul-06-22 08:00AM	Oncocyte Presents DetermaIO Data in Podium Presentation at ESMO World Congress on Gastrointestinal Cancer 2022 (GlobeNewswire)
Jun-22-22 08:00AM	Oncocyte Hosting Key Opinion Webinar on the Role of DetermaIO and the Tumor Microenvironment in Clinical Practice (GlobeNewswire)
Jun-15-22 07:15AM	How Much Of OncoCyte Corporation (NASDAQ:OCX) Do Insiders Own? (Simply Wall St.)
May-26-22 05:00PM	Oncocyte Presents DetermaIO Data at ASCO 2022 Supporting the Tests Potential to Expand the Clinical Use of Immunotherapy (GlobeNewswire)
May-11-22 04:05PM	Oncocyte Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-05-22 08:00AM	Oncocyte Completes Validation of TheraSure Transplant Monitor Test (GlobeNewswire)
Apr-28-22 04:01PM	Oncocyte to Announce First Quarter 2022 Financial Results (GlobeNewswire)
Apr-27-22 04:30PM	Oncocyte to Present New Data at ASCO 2022 Underpinning Pan-Cancer Clinical Utility of DetermaIO (GlobeNewswire)
Apr-22-22 09:26AM	A number of insiders bought OncoCyte Corporation (NASDAQ:OCX) stock last year, which is great news for shareholders (Simply Wall St.)
Apr-13-22 10:01PM	Oncocyte Corporation Announces Pricing of Public Offering of Common Stock and Warrants (GlobeNewswire)
05:12PM	Oncocyte Corporation Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire)
05:10PM	Oncocyte Corporation Announces Pricing of Registered Direct Offering of 11,765 Shares of Series A Convertible Preferred Stock (GlobeNewswire)
Apr-11-22 08:00AM	Oncocyte Presents Confirmatory Data for DetermaIO at the American Association for Cancer Research Annual Meeting 2022 (GlobeNewswire)
Mar-28-22 08:00AM	Oncocyte to Present New Data Confirming Association of IO Score with Response to Immunotherapy Treatment for Bladder Cancer at the American Association for Cancer Research Annual Meeting 2022 (GlobeNewswire)
Mar-10-22 04:05PM	Oncocyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire) +7.69%
Mar-01-22 04:05PM	Oncocyte to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday March 10 (GlobeNewswire)
Feb-21-22 07:26AM	Shareholders in OncoCyte (NASDAQ:OCX) have lost 78%, as stock drops 12% this past week (Simply Wall St.)
Feb-10-22 08:00AM	Oncocyte to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (GlobeNewswire)
Jan-18-22 04:05PM	Oncocyte Announces Development and Co-Marketing Agreement with Thermo Fisher Scientific to Expand Access to Precision Oncology (GlobeNewswire) +15.87%
Jan-06-22 09:43AM	What Type Of Shareholders Make Up OncoCyte Corporation's (NASDAQ:OCX) Share Registry? (Simply Wall St.)
Jan-04-22 08:00AM	Oncocyte Announces Peer-Reviewed Publication in Cancers Showing Utility of DetermaCNI Blood-Only Monitoring Test to Detect Recurrence Following Surgery in Epithelial Ovarian Cancer (GlobeNewswire)
Dec-09-21 06:00PM	Spotlight Poster Presentation at San Antonio Breast Cancer Symposium SABCS 2021 Shows Oncocytes DetermaIO Clinical Test Predicts Response to Immunotherapy in Triple Negative Breast Cancer (GlobeNewswire) -9.81%
Dec-08-21 08:00AM	Oncocyte and Burning Rock Complete Technology Transfer Part Two and Prepare for Scaled Distribution of DetermaRx in China (GlobeNewswire) +10.42%
Dec-06-21 08:00AM	Oncocyte Corporation Hosting Business Update Call (GlobeNewswire)
Dec-02-21 08:00AM	Oncocyte to Present New Data on DetermaIO Clinical Test for Immunotherapy Response in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium 2021 (GlobeNewswire)
Nov-22-21 06:14AM	Is OncoCyte (NASDAQ:OCX) Using Too Much Debt? (Simply Wall St.) -5.43%
Nov-09-21 04:05PM	Oncocyte Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-21 08:00AM	Oncocyte Announces the Clinical Launch of DetermaIO Immunotherapy Response Prediction Test (GlobeNewswire)
Nov-02-21 03:02PM	Will OncoCyte (OCX) Report Negative Earnings Next Week? What You Should Know (Zacks)
Oct-27-21 08:00AM	Oncocyte Strengthens Transplant Intellectual Property Portfolio with US Patent Covering Digital PCR Technology for Early Detection of Organ Transplant Rejection (GlobeNewswire) -5.00%
Oct-26-21 04:05PM	Oncocyte to Report Third Quarter 2021 Financial Results on Tuesday, November 9th (GlobeNewswire)
Oct-08-21 09:46AM	A OncoCyte Corporation (NASDAQ:OCX) insider increased their holdings by 11% last year (Simply Wall St.)
Oct-07-21 08:00AM	Oncocyte Appoints Gisela A. Paulsen as Chief Operating Officer (GlobeNewswire)
Sep-30-21 08:00AM	Oncocyte Publishes Study Demonstrating Predictive Potential for DetermaIO® Test in Triple Negative Breast Cancer (GlobeNewswire)
Sep-20-21 11:35AM	Oncocyte Announces Oral Presentation of New Data on Its DetermaIO Immunotherapy Response Test at the European Society for Medical Oncology Annual Meeting (GlobeNewswire)
08:00AM	Oncocyte Hosting Two-Part Key Opinion Leader Event Series (GlobeNewswire)
Sep-16-21 08:00AM	Modern Healthcare Recognizes Oncocyte as One of the 2021 Best Places to Work in Healthcare (GlobeNewswire)
Sep-13-21 08:00AM	Oncocyte to Present New Data on DetermaIO from NeoTRIPaPDL1 Trial in Oral Presentation from Late-Breaking Abstract at ESMO 2021 (GlobeNewswire)
Sep-07-21 04:05PM	Oncocyte to Participate in the 5th Annual Lake Street Capital Markets Best Ideas Growth Conference (GlobeNewswire)
Aug-23-21 09:13AM	Investors in OncoCyte (NASDAQ:OCX) have made a strong return of 202% over the past year (Simply Wall St.)
Aug-18-21 08:49AM	Is the Options Market Predicting a Spike in OncoCyte (OCX) Stock? (Zacks)
Aug-17-21 08:00AM	Oncocyte Launches First Real-World Evidence (RWE) Registry to Evaluate Biomarker Impact on Early-Stage Lung Cancer Treatment Decisions and Outcomes (GlobeNewswire)
Aug-10-21 04:01PM	Oncocyte Reports Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-09-21 08:00AM	Oncocyte to Participate in Upcoming Investor Events (GlobeNewswire)
Aug-03-21 03:00PM	Will OncoCyte (OCX) Report Negative Earnings Next Week? What You Should Know (Zacks)
Jul-27-21 10:35AM	Oncocyte to Report Second Quarter 2021 Financial Results on Tuesday, August 10 (GlobeNewswire)
Jul-08-21 05:34AM	Here's What OncoCyte Corporation's (NASDAQ:OCX) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Jun-22-21 08:00AM	Oncocyte Celebrates Women Thoracic Surgeons in #ShesMySurgeon Campaign (GlobeNewswire)
Jun-15-21 08:03AM	EchelonDx and Oncocyte Announce Collaboration to Create Seamless Informatics Software to Scale Proprietary Clinical Test Offerings (Business Wire)
Jun-03-21 08:00AM	Oncocyte Announces Collaboration with Gruppo Oncologico del Nord Ovest to Evaluate Oncocytes DetermaIO Test in Colorectal Cancer, the Second Leading Cause of Cancer Mortality Globally (GlobeNewswire) +7.97%
Jun-01-21 08:00AM	Oncocyte Selected as New Day One Launch Site for QIAGENs Companion Diagnostics Test to Identify Patients for Amgens Newly FDA-Approved Drug LUMAKRAS (Sotorasib) For Advanced Stage Lung Cancer (GlobeNewswire)

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BROADWOOD PARTNERS, L.P.	10% Owner	Apr 11 '24	Buy	2.92	2,420,000	7,057,688	4,929,066	Apr 15 07:21 PM
Arno Andrew	Director	Apr 11 '24	Buy	2.95	33,898	99,999	69,054	Apr 15 06:02 AM
Riggs Josh	CEO and President	Apr 11 '24	Buy	2.95	3,390	10,000	3,505	Apr 15 06:04 AM
KINGSLEY ALFRED D	Director	Jun 14 '23	Buy	0.21	30,000	6,447	469,111	Jun 15 08:13 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OCX

Oncocyte Corporation

Upgrade your FINVIZ experience